<DOC>
	<DOCNO>NCT00002676</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining radiation therapy chemotherapy may kill tumor cell may effective treatment non-Hodgkin 's lymphoma . PURPOSE : Phase II trial study effectiveness combination chemotherapy whole-brain radiation therapy patient primary central nervous system non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Chemotherapy Whole-Brain Radiation Therapy Treating Patients With Primary Central Nervous System Non- Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I. Assess response CHOD ( cyclophosphamide/doxorubicin/vincristine/ dexamethasone ) BVAM ( carmustine/vincristine/cytarabine/methotrexate ) plus whole-brain radiotherapy patient primary central nervous system non-Hodgkin 's lymphoma ( PCNSL ) . II . Assess toxic effect associate treatment . III . Assess survival patient PCNSL receive treatment . IV . Investigate frequency systemic involvement follow-up . V. Identify factor appear associate outcome .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Primary central nervous system nonHodgkin 's lymphoma ( PCNSL ) Clinically diagnose intracranial spaceoccupying lesion Pathology consistent nonHodgkin 's lymphoma review NCCTG Biopsy optional characteristic history , pathognomonic neuroimaging , cytology consistent malignant lymphocyte vitrectomy , CSF , No occult systemic lymphoma prior lymphoma No posttransplant lymphoproliferative disorder Disease measurable evaluable postoperative contrastenhanced CT MRI Postoperative therapy must start within 6 week definitive diagnosis PATIENT CHARACTERISTICS : Age : 18 70 Performance status : ECOG 03 Hematopoietic : WBC least 4,000/mm3 Platelet count least 120,000/mm3 Hepatic : Bilirubin great 2 time normal AST great 2 time normal Renal : Creatinine great 1.5 time normal Cardiovascular : No heart failure No uncontrolled arrhythmia Pulmonary : No severe pulmonary failure Other : No serious uncontrolled infection No active bleeding No AIDS HIVpositive serology No prior organ transplant No pregnant nursing woman Negative pregnancy test require fertile woman Adequate contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Corticosteroids allow dose fixed decrease least 1 week prior baseline scan Radiotherapy : No prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
</DOC>